Neuraly debuts with $36M to target neurodegenerative diseases

Neurodegeneration company Neuraly Inc. (Germantown, Md.) launched Wednesday with a tranched $36 million series A round led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean

Read the full 252 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE